Loading...
XSTO
CLS B
Market cap6mUSD
, Last price  
SEK
Name

Clinical Laserthermia Systems AB

Chart & Performance

D1W1MN
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
129.42%
Rev. gr., 5y
67.47%
Revenues
19m
+127.04%
149,999199,997350,484349,99800003,637,457614,4481,808,0001,426,0001,332,0002,245,0006,268,0008,273,00018,783,000
Net income
-48m
L-40.32%
-671,199-1,977,200-4,953,543-6,974,800-12,696,862-18,325,183-17,841,372-16,594,960-26,948,911-21,263,000-32,854,999-43,375,000-57,939,000-63,615,000-70,660,000-79,792,000-47,623,000
CFO
0k
P
-69,299-2,278,091-4,917,994-5,959,696-12,046,075-18,302,855-15,742,905-18,676,887-19,626,742-24,386,339-38,724,000-39,122,000-55,407,000-66,175,000-70,688,889-66,455,0000
Earnings
May 15, 2025

Profile

Clinical Laserthermia Systems AB (publ) develops treatment tools for diseased tissue under the TRANBERG brand in Sweden. The company offers TRANBERG, a thermal therapy system designed to deliver laser energy to heat the target tissue. It also provides mobile laser unit, a controlling component with a wavelength of 1064 nanometers provides multiple options to control treatment. In addition, the company offers various gauge laser applicators, as well as provides temperature and treatment monitoring devices. Clinical Laserthermia Systems AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.
URL
https://clinicallaser.se/
IPO date
Apr 16, 2009
Employees
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
18,783
127.04%
8,273
31.99%
6,268
179.20%
Cost of revenue
8,364
7,406
11,188
Unusual Expense (Income)
NOPBT
10,419
867
(4,920)
NOPBT Margin
55.47%
10.49%
Operating Taxes
(576)
Tax Rate
NOPAT
10,419
867
(4,343)
Net income
(47,623)
-40.32%
(79,792)
12.92%
(70,660)
11.07%
Dividends
Dividend yield
Proceeds from repurchase of equity
71,100
107,372
57,044
BB yield
-176.43%
-115.82%
-83.50%
Debt
Debt current
216
231
30,678
Long-term debt
232
454
Deferred revenue
Other long-term liabilities
36,612
Net debt
(22,058)
(14,646)
19,972
Cash flow
Cash from operating activities
(66,455)
(70,689)
CAPEX
(2,462)
(2,143)
(562)
Cash from investing activities
(7,470)
(5,497)
(886)
Cash from financing activities
71,100
76,694
61,844
FCF
6,197
1,506
(10,237)
Balance
Cash
22,506
15,331
10,589
Long term investments
118
Excess cash
21,567
14,917
10,393
Stockholders' equity
23,660
30,175
(398,092)
Invested Capital
44,343
29,065
436,189
ROIC
28.39%
0.37%
ROCE
15.81%
1.97%
EV
Common stock shares outstanding
11,011
3,359
417
Price
3.66
-86.74%
27.60
-83.15%
163.80
-80.00%
Market cap
40,300
-56.53%
92,702
35.70%
68,314
-71.00%
EV
15,206
75,815
86,934
EBITDA
10,419
3,575
(2,470)
EV/EBITDA
1.46
21.20
Interest
433
9,760
10,972
Interest/NOPBT
4.16%
1,125.15%